170 studies found for:    regeneron
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
2 Completed A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
Condition: Sciatica
Interventions: Drug: REGN475;   Drug: Placebo Injection
3 Recruiting Study to Determine the Safety and Effectiveness of Dupilumab (REGN668/SAR231893) for Treatment of Atopic Dermatitis (AD)
Condition: Atopic Dermatitis (AD)
Interventions: Drug: dupilumab;   Drug: placebo
4 Recruiting Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)
Condition: Healthy Volunteers
Interventions: Drug: REGN1033 (SAR391786);   Other: placebo
5 Recruiting Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Interventions: Drug: Sarilumab;   Drug: Tocilizumab
6 Recruiting Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers
Condition: Healthy Volunteers
Interventions: Drug: REGN2009;   Other: placebo
7 Recruiting Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Condition: Solid Tumors
Interventions: Drug: nesvacumab (REGN910/ SAR307746);   Drug: aflibercept (ziv-aflibercept)
8 Recruiting An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193
Condition: Healthy Volunteers
Interventions: Drug: REGN1193;   Other: Placebo
9 Not yet recruiting Study of REGN910 in Patients With Diabetic Macular Edema (DME)
Condition: Diabetic Macular Edema
Interventions: Drug: REGN910;   Drug: placebo;   Drug: IVT aflibercept injection
10 Recruiting Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
Condition: Neovascular Wet Age-related Macular Degeneration (AMD)
Intervention: Drug: REGN2176-3
11 Recruiting Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Condition: Cancer
Interventions: Drug: REGN1400;   Drug: Erlotinib;   Drug: Cetuximab
12 Recruiting Study of Nesvacumab (REGN910/ SAR307746)
Condition: Solid Tumors
Intervention: Drug: nesvacumab (REGN910/ SAR307746)
13 Recruiting Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
Condition: Metabolic Disorders
Interventions: Drug: REGN1500;   Drug: placebo
14 Recruiting Study to Assess the Safety and Tolerability of Single Doses of REGN1500
Condition: Healthy Volunteers
Interventions: Drug: REGN1500;   Drug: placebo
15 Recruiting Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: placebo
16 Recruiting Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
Condition: Sarcopenia
Interventions: Drug: REGN1033 (SAR391786);   Drug: placebo
17 Active, not recruiting The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Condition: Central Serous Chorioretinopathy
Intervention: Drug: Intravitreal Aflibercept Injection
18 Completed Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Condition: Cancer
Intervention: Biological: ziv-aflibercept
19 Completed Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Condition: Cancer
Intervention: Biological: ziv-aflibercept
20 Completed VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: ziv-aflibercept

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years